Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy

Xie, Qiuping; Liu, Haiyan; Guo, Zeyi; Wu, Yanping; He, Guolin; Cai, Lei; Pan, Mingxin; Fu, Shunjun

doi:10.3389/fmolb.2021.810251

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the overall survival of patients with HCC has improved with advancements in diagnosis and treatment, the majority of Asian patients are diagnosed at an advanced stage, necessitating more aggressive approaches (11). At our center, nearly half of the patients on the LT waiting list have HCC and >70% of patients exceed the Milan criteria.…”

Section: Discussionmentioning

confidence: 98%

Successful liver transplantation with ctDNA clearance after PD‑1 inhibitor plus FOLFOX‑HAIC treatment in HCC: A case report

Zhao,

Chen,

Yang

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

Liver transplantation (LT) is the primary treatment for patients with early-stage hepatocellular carcinoma (HCC). However, the 5-year survival rate after LT remains low for patients with advanced HCC. Recently, combining programmed cell death protein-1 (PD-1) inhibitors with hepatic arterial infusion chemotherapy (HAIC) has achieved promising outcomes in advanced HCC treatment. However, there is a lack of sufficient clinical data demonstrating its effectiveness as a pre-LT down-staging treatment. The current study presented a case of advanced HCC beyond the Milan criteria who underwent LT and achieved a favorable outcome following PD-1 inhibitor combined with FOLFOX-HAIC therapy. Of note, due to treatment-induced tumor necrosis, precise post-treatment tumor size evaluation became challenging. To address this, circulating tumor DNA (ct-DNA) clearance was used as the LT criterion. After three cycles of Pembrolizumab and FOLFOX-HAIC therapy, the patient's serum ctDNA became undetectable and serum α-fetoprotein levels returned to normal. Magnetic resonance imaging results also revealed a significant reduction in liver tumor size post down-staging treatment. Subsequent to LT, serum ctDNA was monitored every two months, consistently yielding diminished results. There were no clinical signs of recurrence 19 months post-LT. These findings suggest that Pembrolizumab in combination with FOLFOX-HAIC may serve as a potential down-staging strategy prior to LT. In addition, ctDNA clearance may be considered a viable biomarker for LT eligibility.

show abstract

Section: Discussionmentioning

confidence: 98%